203 related articles for article (PubMed ID: 23128576)
1. Use of bone turnover markers in clinical practice.
Biver E
Curr Opin Endocrinol Diabetes Obes; 2012 Dec; 19(6):468-73. PubMed ID: 23128576
[TBL] [Abstract][Full Text] [Related]
2. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study.
Ardawi MS; Maimani AA; Bahksh TA; Rouzi AA; Qari MH; Raddadi RM
Bone; 2010 Oct; 47(4):804-14. PubMed ID: 20659600
[TBL] [Abstract][Full Text] [Related]
3. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.
Vasikaran S; Eastell R; Bruyère O; Foldes AJ; Garnero P; Griesmacher A; McClung M; Morris HA; Silverman S; Trenti T; Wahl DA; Cooper C; Kanis JA;
Osteoporos Int; 2011 Feb; 22(2):391-420. PubMed ID: 21184054
[TBL] [Abstract][Full Text] [Related]
4. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
Delmas PD; Munoz F; Black DM; Cosman F; Boonen S; Watts NB; Kendler D; Eriksen EF; Mesenbrink PG; Eastell R;
J Bone Miner Res; 2009 Sep; 24(9):1544-51. PubMed ID: 19338427
[TBL] [Abstract][Full Text] [Related]
5. Towards optimising the provision of laboratory services for bone turnover markers.
Vasikaran SD; Chubb SA; Schneider HG
Pathology; 2014 Jun; 46(4):267-73. PubMed ID: 24798169
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring anti-osteoporotic therapy: bone mineral density or markers of bone turnover].
Pedersen SB; Rand MS; Eiken PA; Jørgensen NR
Ugeskr Laeger; 2018 Aug; 180(32):. PubMed ID: 30070630
[TBL] [Abstract][Full Text] [Related]
7. Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis.
Eastell R; Reid DM; Vukicevic S; Ensrud KE; LaCroix AZ; Thompson JR; Thompson DD; Cummings SR
Bone; 2012 May; 50(5):1135-40. PubMed ID: 22348983
[TBL] [Abstract][Full Text] [Related]
8. Role of biochemical markers in the management of osteoporosis.
Henriksen K; Christiansen C; Karsdal MA
Climacteric; 2015; 18 Suppl 2():10-8. PubMed ID: 26507704
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis.
Biver E; Chopin F; Coiffier G; Brentano TF; Bouvard B; Garnero P; Cortet B
Joint Bone Spine; 2012 Jan; 79(1):20-5. PubMed ID: 21724445
[TBL] [Abstract][Full Text] [Related]
10. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
Bonnick SL; Shulman L
Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
[TBL] [Abstract][Full Text] [Related]
11. Determinants of bone turnover markers in healthy premenopausal women.
Adami S; Bianchi G; Brandi ML; Giannini S; Ortolani S; DiMunno O; Frediani B; Rossini M;
Calcif Tissue Int; 2008 May; 82(5):341-7. PubMed ID: 18470550
[TBL] [Abstract][Full Text] [Related]
12. Bone turnover markers in the management of postmenopausal osteoporosis.
Brown JP; Albert C; Nassar BA; Adachi JD; Cole D; Davison KS; Dooley KC; Don-Wauchope A; Douville P; Hanley DA; Jamal SA; Josse R; Kaiser S; Krahn J; Krause R; Kremer R; Lepage R; Letendre E; Morin S; Ooi DS; Papaioaonnou A; Ste-Marie LG
Clin Biochem; 2009 Jul; 42(10-11):929-42. PubMed ID: 19362543
[TBL] [Abstract][Full Text] [Related]
13. Bone Turnover Markers: Use in Fracture Prediction.
Vilaca T; Gossiel F; Eastell R
J Clin Densitom; 2017; 20(3):346-352. PubMed ID: 28716498
[TBL] [Abstract][Full Text] [Related]
14. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
15. Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis.
Vasikaran SD; Miura M; Pikner R; Bhattoa HP; Cavalier E;
Calcif Tissue Int; 2023 Feb; 112(2):148-157. PubMed ID: 34846540
[TBL] [Abstract][Full Text] [Related]
16. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.
Baim S; Miller PD
J Bone Miner Res; 2009 Apr; 24(4):561-74. PubMed ID: 19257812
[TBL] [Abstract][Full Text] [Related]
17. High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study.
Szulc P; Montella A; Delmas PD
Ann Rheum Dis; 2008 Sep; 67(9):1249-55. PubMed ID: 18065499
[TBL] [Abstract][Full Text] [Related]
18. [Biochemical markers of bone remodeling].
Briot K; Roux C
Gynecol Obstet Fertil; 2005 Dec; 33(12):1009-13. PubMed ID: 16316769
[TBL] [Abstract][Full Text] [Related]
19. [Clinical usefulness of bone turnover markers in the management of osteoporosis].
Yano S
Rinsho Byori; 2013 Sep; 61(9):852-9. PubMed ID: 24369600
[TBL] [Abstract][Full Text] [Related]
20. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
Garnero P; Delmas PD
Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
